CMS TAVR Update: Who will capitalize quickly and drive growth through coverage expansion?

S2N Health CMS TAVR Update: Who will capitalize quickly and drive growth through coverage expansion?

CMS TAVR Update: Who will capitalize quickly and drive growth through coverage expansion?

On September 10, 2026, CMS finalized its updated National Coverage Determination (NCD) for transcatheter aortic valve replacement (TAVR), closing out a review process that began after Edwards Lifesciences petitioned the agency in December 2025 on the strength of its EARLY TAVR trial data. This update delivers most of what CMS previewed in its June 2026 proposal, marking the first major overhaul of Medicare’s TAVR coverage policy since the original 2012 determination.

What is in the CMS TAVR Update?

Coverage for Asymptomatic Patients 

Asymptomatic patients with severe aortic stenosis were previously excluded from routine TAVR coverage. The update means TAVRs are now covered through Medicare with a Coverage with Evidence Development (CED) requirement in place. 

Reduced Restrictions for Symptomatic Patients

The CED requirement for symptomatic patients has been removed, meaning these cases no longer need to be performed within a CMS-approved study.

Single-operator Procedures Permitted 

In addition to dropping the requirement of having two qualified TAVI operators perform the procedure, CMS also redefined a qualified TAVI operator based on specialty and case volumes. Importantly, CMS will still cover two-operator cases when the heart team deems it appropriate.

Reinforced Core Safeguards 

TAVR facilities are still required to have on-site cardiac surgery and ICU capabilities, and the multidisciplinary heart team requirement stays in place—now with added flexibility to triage via chart review ahead of a required in-person evaluation by a TAVI operator.

Physician societies responded favorably: SCAI’s president called the update a “meaningful modernization of Medicare coverage,” and a joint SCAI/ACC/STS statement emphasized that registry participation and outcomes reporting will remain central to maintaining quality as access grows.

What This Means for the Medtech Market

For device makers, this is an obvious tailwind. Edwards Lifesciences and Medtronic both issued statements welcoming the changes, and analysts have flagged Edwards as the more direct beneficiary given its role in generating the asymptomatic-patient evidence base.

 However, coverage expansion and real-world uptake are two different things. Translating this policy shift into procedure volume will hinge on which hospitals have the surgical and ICU infrastructure to onboard asymptomatic patients, how quickly heart teams adapt their referral and triage pathways, and where single-operator flexibility will result in actual changes to site-level economics and throughput.

How S2N Health Helps MedTech Teams Capture the Opportunity

Medtech teams hoping to capitalize on this opportunity will have to do more than simply watch the policy shift play out. Companies need to know which of their (and their competitor’s) sites are positioned to expand TAVR volume, which physicians and administrators will drive local adoption, and where to focus their efforts geographically to capture the addressable asymptomatic TAVR market efficiently. These are exactly the kinds of questions S2N Health’s end-to-end market intelligence and physician research capabilities are built to answer.

    • Identify sites with the surgical/ICU infrastructure and heart-team readiness to expand into asymptomatic TAVR.

    • Map physician and administrative stakeholders shaping local referral and adoption pathways.

    • Size the addressable asymptomatic-patient opportunity by geography and account.

Ready to capture the opportunity? 

Contact S2N Health to see how we can help you target the right sites and stakeholders as TAVR access expands.

Sources

CMS — TAVR National Coverage Determination Tracking Sheet

SCAI — Final TAVR NCD Released: Key Changes and Next Steps

TCTMD — CMS Finalizes Anticipated Updates to National Coverage of TAVI

MedTech Dive — CMS Expands TAVR Medicare Coverage to Asymptomatic Patients

Let’s Get Started

Mattis adipiscing nunc nullam justo ipsum lacus. Tortor vulputate sed amet dolor.

Paul LaViolette Form - New Pop Up Form